# Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Study · id `cardio:ct-nct02689206` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02689206](<https://clinicaltrials.gov/study/NCT02689206>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02689206

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT02689206. Randomized; double masking; primary purpose treatment. Start 2016-02-17 (actual); primary completion 2017-01-25 (actual). Results posted on 2018-05-21.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT02689206, source copy `cardio:ctgov-nct02689206-2020-02-25`, retrieved 2026-10-26)
- Started: 2016-02-17 (actual) (ClinicalTrials.gov record NCT02689206, source copy `cardio:ctgov-nct02689206-2020-02-25`, retrieved 2026-10-26)
- Primary completion: 2017-01-25 (actual) (ClinicalTrials.gov record NCT02689206, source copy `cardio:ctgov-nct02689206-2020-02-25`, retrieved 2026-10-26)
- Completion: 2017-01-25 (actual) (ClinicalTrials.gov record NCT02689206, source copy `cardio:ctgov-nct02689206-2020-02-25`, retrieved 2026-10-26)
- Results first posted: 2018-05-21 (ClinicalTrials.gov record NCT02689206, source copy `cardio:ctgov-nct02689206-2020-02-25`, retrieved 2026-10-26)
- Countries: United States; Canada; Germany; Russia; Spain (ClinicalTrials.gov record NCT02689206, source copy `cardio:ctgov-nct02689206-2020-02-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02689206-2020-02-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
- Condition: Anaemia
- Intervention (Drug): GSK1278863
- Intervention (Drug): GSK1278863 matching Placebo
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: c217d585cd15f920126ea8a9cdb5bba3c549a257a0dbafb4e4cb79ea40960fd7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
